44 Result(s)

Article

Impact of socioeconomic disparities on outcomes in adults undergoing allogeneic hematopoietic cell transplantation for acute myeloid leukemia

Racial and socioeconomic disparities impact outcomes after chemotherapy and limit access to allogeneic hematopoietic cell transplantation (HCT) in acute myeloid leukemia (AML), yet studies have yielded mixed r...

Daniel J. Olivieri, Megan Othus, Corentin Orvain, Eduardo Rodríguez-Arbolí… in Leukemia (2024)

Article

A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML

Prior experience indicated that use of higher doses of cytarabine during induction for acute myeloid leukemia (AML) with a histone deacetylase inhibitor resulted in high response rates. S1203 was a randomized ...

Guillermo Garcia-Manero, Nikolai A. Podoltsev, Megan Othus, John M. Pagel… in Leukemia (2024)

Article

Evolution of eligibility criteria for non-transplant randomized controlled trials in adults with acute myeloid leukemia

Eligibility criteria for clinical trials are intended to select suitable study subjects but can limit trial participation and generalization of results. While reported for other cancers, non-enrollment rates a...

Corentin Orvain, Megan Othus, Gurleen Johal, Mathilde Hunault-Berger… in Leukemia (2022)

Article

Utility of the Treatment-Related Mortality (TRM) score to predict outcomes of adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation

There is long-standing interest in estimating non-relapse mortality (NRM) after allogeneic hematopoietic cell transplantation (HCT) for AML, but existing tools have limited discriminative capacity. Using singl...

Lucas C. Zarling, Megan Othus, Brenda M. Sandmaier, Filippo Milano, Gary Schoch… in Leukemia (2022)

Article

Long-term survival with mixed chimerism in patients with AML and MDS transplanted after conditioning with targeted busulfan, fludarabine, and thymoglobulin

We evaluated long-term outcome in 40 patients with MDS or AML, transplanted from related or unrelated donors following conditioning with targeted busulfan (Bu, over 4 days), fludarabine (Flu, 120 [n = 23] or 250 ...

Albert C. Yeh, Paul V. O’Donnell, Gary Schoch… in Bone Marrow Transplantation (2022)

Article

Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial

The prospective randomized, placebo-controlled CALGB 10603/RATIFY trial (Alliance) demonstrated a statistically significant overall survival benefit from the addition of midostaurin to standard frontline chemo...

Richard A. Larson, Sumithra J. Mandrekar, Lucas J. Huebner, Ben L. Sanford… in Leukemia (2021)

Article

Optimal dosing of cytarabine in induction and post-remission therapy of acute myeloid leukemia

Roland B. Walter, Frederick R. Appelbaum, Elihu H. Estey in Leukemia (2021)

Article

Comparative analysis of total body irradiation (TBI)-based and non-TBI-based myeloablative conditioning for acute myeloid leukemia in remission with or without measurable residual disease

Linde M. Morsink, Evandro D. Bezerra, Megan Othus, Brent L. Wood, Min Fang… in Leukemia (2020)

Article

Impact of pretransplant measurable residual disease on the outcome of allogeneic hematopoietic cell transplantation in adult monosomal karyotype AML

Allogeneic hematopoietic cell transplantation (HCT) is often unsuccessful for monosomal karyotype (MK) acute myeloid leukemia (AML). To what degree failures are associated with pretransplant measurable residua...

Linde M. Morsink, Megan Othus, Evandro D. Bezerra, Brent L. Wood, Min Fang… in Leukemia (2020)

Article

Early achievement of measurable residual disease (MRD)-negative complete remission as predictor of outcome after myeloablative allogeneic hematopoietic cell transplantation in acute myeloid leukemia

Alexander P. Hoffmann, Ashley L. Besch, Megan Othus… in Bone Marrow Transplantation (2020)

Article

Pre-transplant bone marrow monocytic myeloid-derived suppressor cell frequency is not associated with outcome after allogeneic hematopoietic cell transplantation for acute myeloid leukemia in remission

Colin D. Godwin, Jonathan R. Fromm, Megan Othus… in Bone Marrow Transplantation (2019)

Article

Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials

Megan Othus, Elihu H. Estey, Guillermo Garcia-Manero, Brent L. Wood… in Leukemia (2019)

Article

Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies

Here we quantify and compare the absolute and relative overall survival (OS) benefits conveyed by complete remission (CR) in AML and high-risk MDS, and by CR with incomplete count recovery (CRi) in AML and by ...

Megan Othus, Mikkael A. Sekeres, Sucha Nand, Guillermo Garcia-Manero… in Leukemia (2019)

Article

Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms

Outcomes with “7 + 3” are often unsatisfactory in acute myeloid leukemia (AML). Trials demonstrating improved outcomes with high-dose cytarabine, addition of cladribine, or escalated anthracycline doses prompt...

Anna B. Halpern, Megan Othus, Emily M. Huebner, Bart L. Scott, Pamela S. Becker… in Leukemia (2018)